- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Abbisko Cayman Ltd (2256)
The Abbisko Cayman share price today is 9.85, view HK 2256 stock exchange data. Track the latest Abbisko Cayman share price with real-time updates on 2256 stock performance including market cap, day range, 52-week range and dividend yield. Access 2256 charts, earnings dates and analyst estimates to support your investment decisions.
Hong Kong
Currency in HKD
9.85
+0.10(+1.03%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.70
10.39
52 wk Range
8.34
19.78
2256 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.7010.39
52 wk Range
8.3419.78
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2256 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
21.74
Upside
+120.74%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 21.74
(+120.74% Upside)
Earnings
Latest Release
02-03-2026
EPS / Forecast
-0.44 / --
Revenue / Forecast
-- / --
Compare 2256 to Peers and Sector
Metrics to compare | 2256 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2256PeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.9x | −6.7x | −0.4x | |
PEG Ratio | 0.03 | 0.06 | 0.00 | |
Price/Book | 2.5x | 5.3x | 2.6x | |
Price / LTM Sales | 57.1x | 10.4x | 3.1x | |
Upside (Analyst Target) | 117.5% | 49.1% | 46.0% | |
Fair Value Upside | Unlock | 6.1% | 5.3% | Unlock |
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma. It also engages in the development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia; and ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer. In addition, the company develops drugs in Phase I/Ia clinical trial, including ABSK121 for solid tumors; ABSK112 for non-small cell lung and breast cancers; ABK3376 for non-small cell lung cancer; ABSK131 for solid tumors; ABSK141 for solid tumors; and ABSK051 for solid tumors, as well as ABSK012, which is in preclinical stage for the treatment of rhabdomyosarcoma and solid tumors. Further, it is involved in the development of drugs in IND enabling stage, such as ABSK211, ABSK191, and ABSK192 for solid tumors, as well as P151 for cardiometabolic; and drugs in lead optimization stage comprising P011, P018, P020, and P017 for solid tumors, as well as P023 for obesity and P022 for atopic dermatitis, asthma, and chronic obstructive pulmonary disease. Additionally, the company provides advisory and management services. Abbisko Cayman Limited was founded in 2016 and is headquartered in Shanghai, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Abbisko Cayman (2256) Share Price Today?
The Abbisko Cayman share price today is 9.85.
What is the current Abbisko Cayman (2256) share price and day range?
As of 27-08-2026, the Abbisko Cayman share price is 9.85, with a previous close of 9.85. The share price has ranged from 9.70 to 10.39 today, while the 52-week range spans from 8.34 to 19.78.
What Is the Abbisko Cayman Market Cap?
As of today, Abbisko Cayman market cap is 6.54B.
What Is the Abbisko Cayman (2256) Share Price Target?
The average 12-month share price target for Abbisko Cayman is 21.74, with a high estimate of 26.50530736 and a low estimate of 17.68342471. 8 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +120.74% Upside potential.
What Is Abbisko Cayman's Earnings Per Share (TTM)?
The Abbisko Cayman EPS (TTM) is -0.74.
From a Technical Analysis Perspective, Is 2256 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Abbisko Cayman Trade On?
Abbisko Cayman is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for Abbisko Cayman?
The stock symbol for Abbisko Cayman is "2256."
How Many Times Has Abbisko Cayman Stock Split?
Abbisko Cayman has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.